张峥,李佳雨,白元

• 1:中国人民解放军海军军医大学第一附属医院心内科
• 2:中国人民解放军海军军医大学第一附属医院基础医学院

摘要(Abstract)：

心房心肌病（AC）是一种以心房重构为主要特征的疾病。越来越多的证据表明，AC与缺血性卒中的关系密切，其引发缺血性卒中的机制复杂。目前临床上预防AC导致的缺血性卒中，可以选择抗凝药物、左心耳封堵术等方法。本文结合近期的相关文献，就AC与缺血性卒中的研究历史和定义、AC与缺血性卒中的相关性、AC引发缺血性卒中的可能机制以及预防AC导致缺血性卒中的方法等进行综述。

关键词(KeyWords)： 心房心肌病;缺血性卒中;抗凝;心房颤动

Abstract:

Keywords:

基金项目(Foundation): 长海医院“234学科攀峰计划”项目（2020YXK010）

作者(Author): 张峥,李佳雨,白元

参考文献(References)：

• [1] Pedersen OD, K?ber L, Torp-Pedersen C. Atrial fi brillation and atrial cardiomyopathy—two sides of the same coin[J]? Am Heart J,2004, 147(6):953-955.
• [2] Kottkamp H. Atrial fi brillation substrate:the"unknown species"—from lone atrial fibrillation to fibrotic atrial cardiomyopathy[J].Heart Rhythm, 2012, 9(4):481-482.
• [3] Williams DO, Jones EL, Nagle RE, et al. Familial atrial cardiomyopathy with heart block[J]. Q J Med, 1972, 41(164):491-508.
• [4] Zipes DP. Atrial fibrillation. A tachycardia-induced atrial cardiomyopathy[J]. Circulation, 1997, 95(3):562-564.
• [5] Dong M, Liu T, Li G. Atrial cardiomyopathy--a not yet classifi ed cardiomyopathy[J]? Int J Cardiol, 2011, 151(3):394-396.
• [6]董梅，刘彤，李广平.心房心肌病新进展[J].临床心电学杂志，2018, 27(5):372-380.
• [7] Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies:defi nition,characterisation, and clinical implication[J]. J Arrhythm, 2016, 32(4):247-278.
• [8] Sacco RL, Kasner SE, Broderick JP, et al. An updated defi nition of stroke for the 21st century:a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013, 44(7):2064-2089.
• [9] Adams HP Jr, Bendixen BH, Kappelle LJ,et al. Classifi cation of subtype of acute ischemic stroke. Defi nitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment[J].Stroke, 1993, 24(1):35-41.
• [10] Stalikas N, Doundoulakis I, Karagiannidis E, et al. Prevalence of markers of atrial cardiomyopathy in embolic stroke of undetermined source:a systematic review[J]. Eur J Intern Med,2022. Online ahead of print.
• [11] Su Y, Chen BX, Wang Y, et al. Association of atrial18F-fl uorodeoxyglucose uptake and prior ischemic stroke in non-atrial fi brillation patients[J]. J Nucl Cardiol, 2022. Online ahead of print.
• [12] Guichard JB, Nattel S. Atrial cardiomyopathy:a useful notion in cardiac disease management or a passing fad[J]? J Am Coll Cardiol, 2017, 70(6):756-765.
• [13] Nakano M, Kondo Y, Nakano M, et al. Atrial high-rate episodes and atrial cardiomyopathy on the future stroke[J]. J Cardiol, 2019,74(4):394-395.
• [14] Turakhia MP, Ziegler PD, Schmitt SK, et al. Atrial fi brillation burden and short-term risk of stroke:case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices[J].Circ Arrhythm Electrophysiol, 2015, 8(5):1040-1047.
• [15] Gladstone DJ, Dorian P, Spring M, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke:results from the EMBRACE trial[J]. Stroke, 2015, 46(4):936-941.
• [16] Dewland TA, Vittinghoff E, Mandyam MC, et al. Atrial ectopy as a predictor of incident atrial fi brillation:a cohort study[J]. Ann Intern Med, 2013, 159(11):721-728.
• [17] Hisamatsu T, Miura K, Fujiyoshi A, et al. Association between excessive supraventricular ectopy and subclinical cerebrovascular disease:a population-based study[J]. Eur J Neurol, 2019, 26(9):1219-1225.
• [18] Larsen BS, Kumarathurai P, Falkenberg J, et al. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation[J]. J Am Coll Cardiol, 2015, 66(3):232-241.
• [19] Pinho J, Braga CG, Rocha S, et al. Atrial ectopic activity in cryptogenic ischemic stroke and TIA:a risk factor for recurrence[J].J Stroke Cerebrovasc Dis, 2015, 24(2):507-510.
• [20] Mayasi Y, Helenius J, Mcmanus DD, et al. Atrial fi brillation is associated with anterior predominant white matter lesions in patients presenting with embolic stroke[J]. J Neurol Neurosurg Psychiatry,2018, 89(1):6-13.
• [21] Bayés-De-Luna A, Martínez-Sellés M, Elosua R, et al. Relation of advanced interatrial block to risk of atrial fi brillation and stroke[J].Am J Cardiol, 2020, 125(11):1745-1748.
• [22] Lacalzada-Almeida J, Izquierdo-Gómez MM, García-Niebla J, et al. Advanced interatrial block is a surrogate for left atrial strain reduction which predicts atrial fi brillation and stroke[J]. Ann Noninvasive Electrocardiol, 2019, 24(4):e12632.
• [23] Sun H, Gaspo R, Leblanc N, et al. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia[J].Circulation, 1998, 98(7):719-727.
• [24] Hohnloser SH, Capucci A, Fain E, et al. ASymptomatic atrial fi brillation and stroke evaluation in pacemaker patients and the atrial fi brillation reduction atrial pacing trial(ASSERT)[J]. Am Heart J,2006, 152(3):442-447.
• [25] Ip J, Waldo AL, Lip GY, et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defi brillator and CRT-D devices:rationale,design, and clinical characteristics of the initially enrolled cohort the impact study[J]. Am Heart J, 2009, 158(3):364-370.
• [26] Pastori D, Lip GYH, Farcomeni A, et al. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants[J]. Int J Cardiol, 2018, 264:58-63.
• [27] Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fi brosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fi brillation[J]. J Am Coll Cardiol, 2011, 57(7):831-838.
• [28] Floria M, Blommaert D, Deceuninck O, et al. Incidence of left atrial thrombus prior to catheter ablation of atrial fi brillation:is it time for atrial cardiomyopathy evaluation[J]? J Cardiovasc Electrophysiol, 2018, 29(1):e4.
• [29] Russo C, Jin Z, Liu R, et al. LA volumes and reservoir function are associated with subclinical cerebrovascular disease:the CABL(cardiovascular abnormalities and brain lesions)study[J]. JACC Cardiovasc Imaging, 2013, 6(3):313-323.
• [30] Habibi M, Zareian M, Ambale VB, et al. Left atrial mechanical function and incident ischemic cerebrovascular events independent of AF:insights from the MESA study[J]. JACC Cardiovasc Imaging,2019, 12(12):2417-2427.
• [31] Russo C, Jin Z, Homma S, et al. LA phasic volumes and reservoir functionin the elderly by real-time 3D echocardiography:normal values, prognostic significance, and clinical correlates[J]. JACC Cardiovasc Imaging, 2017,10(9):976-985.
• [32] Kamel H. Does left atrial mechanical dysfunction contribute to a thrombogenic atrial myopathy[J]? JACC Cardiovasc Imaging,2019,12(12), 2428-2430.
• [33] Sonaglioni A, Lonati C, Lombardo M, et al. Incremental prognostic value of global left atrial peak strain in women with newonset gestational hypertension[J]. Journal Hypertens, 2019, 37(8):1668-1675.
• [34] Corban MT, Godo S, Burczak DR, et al. Coronary endothelial dysfunction is associated with increased risk of incident atrial fi brillation[J]. J Am Heart Assoc, 2020, 9(8):e014850.
• [35] Martin DT, Bersohn MM, Waldo AL, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices[J].Eur Heart J, 2015, 36(26):1660-1668.
• [36] Boccanelli A. Beyond CHA2DS2-VASc in atrial fi brillation:the atrium and the risk of stroke[J]. Eur Heart J Suppl, 2020, 22:E30-E33.
• [37] January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2):e125-e151.
• [38] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fi brillation:a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921):955-962.
• [39] Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure:lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol,2014, 63(12):1123-1133.
• [40] Dmour BA, Miftode RS, Iliescu Halitchi D, et al. Latest insights into mechanisms behind atrial cardiomyopathy:it is not always about ventricular function[J]. Diagnostics, 2021, 11(3):449.
• [41] Hammw?hner M, Bukowska A,Mahardika W,et al. Clinical importance of atrial cardiomyopathy[J]. Int J Cardiol,2019,287:174-180.
• [42] Shao Q, Meng L, Lee S, et al. Empaglifl ozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats[J]. Cardiovasc Diabetol,2019,18(1):165.
• [43] Kamel H, Longstreth WT Jr, Tirschwell DL, et al. The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial:rationale and methods[J]. Int J Stroke,2019,14(2):207-214.
• [44] Geisler T, Poli S, Meisner C, et al. Apixaban for treatment of embolic stroke of undetermined source(ATTICUS randomized trial):rationale and study design[J]. Int J Stroke, 2017, 12(9):985-990.
• [45] Kotadia ID, Sim I, Mukherjee R, et al. Secondary stroke prevention following embolic stroke of unknown source in the absence of documented atrial fi brillation:a clinical review[J]. J Am Heart Assoc, 2021, 10(13):e021045.
• [46] Holmes DR Jr, Reddy VY, Gordon NT, et al. Long-term safety and e ffi cacy in continued access left atrial appendage closure registries[J]. J Am Coll Cardiol, 2019, 74(23):2878-2889.
• [47] Boersma LV, Ince H, Kische S, et al. Evaluating realworld clinical outcomes in atrial fi brillation patients receiving the WATCHMAN left atrial appendage closure technology：fi nal 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage[J]. Circ Arrhythm Electrophysiol, 2019,12(4):e006841.